A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

Clinical trial NCT05318326 · UNKNOWN

Trial details

NCT number: NCT05318326
Sponsor: Chengdu Easton Biopharmaceuticals Co,Ltd
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Type 2 Diabetes

Start date: 2022-01-01
Primary completion: 2024-12-31
Enrollment: 450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.